Phase II evaluation of Gleevec [imatinib] combined with Camptosar [irinotecan] plus Paraplatin [carboplatin] in patients with previously untreated extensive stage SCLC [small cell lung cancer]

Trial Profile

Phase II evaluation of Gleevec [imatinib] combined with Camptosar [irinotecan] plus Paraplatin [carboplatin] in patients with previously untreated extensive stage SCLC [small cell lung cancer]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Imatinib (Primary) ; Carboplatin; Irinotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2008 Status changed from in prgress to completed.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top